الفهرس Only 14 pages are availabe for public view
 |  | from | 122 |  |  |
| | | from | 122 | | |
Abstract
We report in this study that the DNA-binding drug
Mithramycin is a potent inducer of fetal hemoglobin (HbF)
production in erythroid cells from healthy human subjects and -
thalassemia patients.
Erythroid precursors derived from peripheral blood were
grown in 2-phase liquid culture. In this procedure, early
erythroid progenitors proliferate and differentiate during phase 1
(in the absence of erythropoietin) into late progenitors. In phase
2, in the presence of erythropoietin, the latter cells continue their
proliferation and mature into Hb-containing orthochromatic
normoblasts. Compounds were added on days 4 to 5 of phase 2
(when cells started to synthesize Hb), and cells were harvested
on day 12.